NewsBenzingaBristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By... Bristol Myers Squibb Announces Topline Results From Unit RayzeBio's Planned Interim Analysis Of ACTION-1 Trial; RYZ101 Study Met Primary Endpoint With Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival By... Benzinga 2026.10.12 11:03 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on PENN Entertainment, Lowers Price Target to $22 HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $85 Price Target Alphabet Stock Rises: What's Going On? $1000 Invested In Agilent Technologies 10 Years Ago Would Be Worth This Much Today Wells Fargo Maintains Equal-Weight on MGM Resorts International, Lowers Price Target to $29 Why Is Applied Digital Stock Surging on Monday?
